Review
Version 1
Preserved in Portico This version is not peer-reviewed
Platelets and Thrombotic Antiphospholipid Syndrome
Version 1
: Received: 4 January 2024 / Approved: 5 January 2024 / Online: 5 January 2024 (07:11:24 CET)
A peer-reviewed article of this Preprint also exists.
Tohidi-Esfahani, I.; Mittal, P.; Isenberg, D.; Cohen, H.; Efthymiou, M. Platelets and Thrombotic Antiphospholipid Syndrome. J. Clin. Med. 2024, 13, 741. Tohidi-Esfahani, I.; Mittal, P.; Isenberg, D.; Cohen, H.; Efthymiou, M. Platelets and Thrombotic Antiphospholipid Syndrome. J. Clin. Med. 2024, 13, 741.
Abstract
Antiphospholipid antibody syndrome (APS) is an autoimmune disorder characterised by thrombosis and the presence of antiphospholipid antibodies (aPL): lupus anticoagulant and/or IgG/IgM anti-β2-glycoprotein I and anticardiolipin antibodies. APS carries significant morbidity for a relatively young patient population from recurrent thrombosis in any vascular bed (arterial, venous or microvascular), often despite current standard of care, which is anticoagulation with vitamin K antagonists (VKA). Platelets have established roles in thrombosis at any site, and platelet hyperreactivity is clearly demonstrated in the pathophysiology of APS. Together with excess thrombin generation, platelet activation and aggregation are the common end result of all the pathophysiological pathways leading to thrombosis in APS. However, antiplatelet therapies play little role in APS, reserved as a possible option of low dose aspirin in addition to VKA in arterial or refractory thrombosis. This review outlines the current evidence and mechanisms for excessive platelet activation in APS, how it plays a central role in APS-related thrombosis, what evidence for antiplatelets is available in clinical outcomes studies and potential future avenues to define how to target platelet hyperreactivity better with minimal impact on haemostasis.
Keywords
Antiphospholipid syndrome; antiphospholipid antibodies; thrombosis; platelets; antiplatelets
Subject
Medicine and Pharmacology, Hematology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment